EB-203

EyebioKorea, Inc. · Phase 2 active Small molecule

At a glance

Generic name	EB-203
Sponsor	EyebioKorea, Inc.
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Trial to Evaluate the Safety and Efficacy of EB-203 in Patients With Neovascular Age-related Macular Degeneration (PHASE2)
Safety, Tolerability and Pharmacokinetics of EB-203 Eye Drops in Healthy Volunteers (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

EB-203 CI brief — competitive landscape report
EB-203 updates RSS · CI watch RSS
EyebioKorea, Inc. portfolio CI